Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation

MLA

Scott Kopetz, et al. “Phase 1b/2 Study of Binimetinib (BINI) in Combination with Nivolumab (NIVO) or NIVO plus Ipilimumab (IPI) in Patients (Pts) with Previously Treated Microsatellite-Stable (MSS) Metastatic Colorectal Cancer (MCRC) with RAS Mutation.” Journal of Clinical Oncology, vol. 36, Feb. 2018, p. TPS870. EBSCOhost, https://doi.org/10.1200/jco.2018.36.4_suppl.tps870.

APA

Scott Kopetz, Mark R. Middleton, P T Eves, A P Boyd, V Bozon, Johanna C. Bendell, & Schellens Jhm. (2018). Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation. Journal of Clinical Oncology, 36, TPS870. https://doi.org/10.1200/jco.2018.36.4_suppl.tps870

Chicago

Scott Kopetz, Mark R. Middleton, P T Eves, A P Boyd, V Bozon, Johanna C. Bendell, and Schellens Jhm. 2018. “Phase 1b/2 Study of Binimetinib (BINI) in Combination with Nivolumab (NIVO) or NIVO plus Ipilimumab (IPI) in Patients (Pts) with Previously Treated Microsatellite-Stable (MSS) Metastatic Colorectal Cancer (MCRC) with RAS Mutation.” Journal of Clinical Oncology 36 (February): TPS870. doi:10.1200/jco.2018.36.4_suppl.tps870.